Tandem Diabetes Faces Securities Claims After 19.9% Stock Drop Due to Misleading Information
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock dropped 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, indicating severe market concerns over the company's transparency in communications.
- Legal Investigation Initiated: The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes for allegedly issuing misleading business information, suggesting that investors may face losses and have the right to seek compensation through a class action, further intensifying scrutiny on the company's governance.
- Investor Rights Protection: Affected investors can join the class action without upfront fees through a contingency fee arrangement, highlighting the proactive role of legal firms in safeguarding investor rights, which may impact future investor confidence in the company.
- Industry Implications: This incident not only affects Tandem Diabetes' stock but may also raise regulatory and transparency expectations across the medical device industry, prompting other companies to enhance their information disclosure practices to mitigate similar risks.
TNDM.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 22.71 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
7 Buy
10 Hold
0 Sell
Moderate Buy
Current: 20.710
Low
14.00
Averages
22.71
High
55.00
Current: 20.710
Low
14.00
Averages
22.71
High
55.00
Morgan Stanley
Equal Weight
maintain
$17 -> $23
2025-12-02
New
Reason
Morgan Stanley
Price Target
$17 -> $23
2025-12-02
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Tandem Diabetes to $23 from $17 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Morgan Stanley
Equal Weight
maintain
$13 -> $17
2025-11-10
Reason
Morgan Stanley
Price Target
$13 -> $17
2025-11-10
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Tandem Diabetes to $17 from $13 and keeps an Equal Weight rating on the shares.
Baird
Neutral
maintain
$16 -> $18
2025-11-07
Reason
Baird
Price Target
$16 -> $18
2025-11-07
maintain
Neutral
Reason
Baird raised the firm's price target on Tandem Diabetes to $18 from $16 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results where pricing tailwinds help but pump volume pressures remain.
Barclays
NULL -> Overweight
maintain
$51 -> $55
2025-11-07
Reason
Barclays
Price Target
$51 -> $55
2025-11-07
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Tandem Diabetes to $55 from $51 and keeps an Overweight rating on the shares. The firm views the company's Q3 report as solid and sees a "healthy" pipeline.
See All Ratings
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What specific misleading information is Tandem Diabetes accused of issuing?
Why did Tandem Diabetes' stock price drop by 19.9% on August 7, 2025?
How might the class action lawsuit impact Tandem Diabetes' future stock performance?
Will the Rosen Law Firm's involvement encourage more shareholders to join the lawsuit?